非小细胞肺癌|【权威发布】非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识( 八 )
52 Takahashi T, Tateishi A, Bychkov A, et al. Remarkable alteration of PD-L1 expression after immune checkpoint therapy in patients with non-small-cell lung cancer: Two autopsy case reports. Int J Mol Sci, 2019, 20(10): 2578. doi: 10.3390/ijms20102578
53 Haratake N, Toyokawa G, Tagawa T, et al. Positive conversion of PD-L1 expression af ter treatments with chemotherapy and nivolumab. Anticancer Res, 2017, 37(10): 5713-5717. doi: 10.21873/ anticanres.12009
54 Shin J, Chung JH, Kim SH, e t al . Ef fec t of pl at inum-ba sed chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat, 2019, 51(3): 1086-1097. doi: 10.4143/ crt.2018.537
55 Rojkó L, Reiniger L, Téglási V, et al. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. J Cancer Res Clin Oncol, 2018, 144(7): 1219-1226. doi: 10.1007/ s00432-018-2642-4
56 Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep, 2016, 6: 20090. doi: 10.1038/srep20090
57 Sakai H, Takeda M, Sakai K, et al. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. Lung Cancer, 2019, 127: 59-65. doi: 10.1016/j.lungcan.2018.11.025
58 Choe EA, Cha YJ, Kim JH, et al. Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. Lung Cancer, 2019, 136: 30-36. doi: 10.1016/j.lungcan.2019.07.027
59 Fujimoto D, Uehara K, Sato Y, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep, 2017, 7(1): 11373. doi: 10.1038/s41598-017-11949-9
60 Omori S, Kenmotsu H, Abe M, et al. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. Int J Clin Oncol, 2018, 23(6): 1052-1059. doi: 10.1007/s10147-018-1305-4
61 Han JJ, Kim DW, Koh J, et al. Change in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancer. Clin Lung Cancer, 2016, 17(4): 263-270. doi: 10.1016/ j.cllc.2015.11.006
推荐阅读
- 肺癌|肺癌的一种特殊转移形式，有时会误诊为间质性肺炎，预后很差
- 早期肺癌|早期肺癌没有症状，这五个幸运儿发现肺癌的方式，您绝对想不到
- 肛裂|“经历非常惨痛”，一名24岁青年的自述：做完痔疮＋肛裂手术之后
- 刘贤伦|肺癌患者打新冠疫苗后医生被迫改治疗方案，村支书否认曾动员
- 肺癌|饿死癌细胞，中国专家取得重大科研成果，有望将肺癌变成慢性病
- 糖尿病|糖尿病惹祸的并非“糖”，而是身体里的这种激素
- 非小细胞肺癌|我国发现导致非小细胞肺癌进展的“新杀手”，系云南专家团队合作研究
- 结节|肺结节＝肺癌＝绝症？这篇文章告诉你区别在哪里
- 肺癌|病例分享｜肺癌精准治疗：口服奥希替尼2月，肿瘤缩小71％
- 慢性阻塞性肺疾病|“重症肺癌”来袭，你了解吗？